Medmix slashes dividends by 80% as stock plunges 24% in one month
Medmix has announced major changes to its dividend policy amid a sharp decline in its stock value. The company's share price has fallen by around 24% over the past month, now trading at CHF 8.66. At the same time, its Relative Strength Index (RSI) has dropped to 17.8, signalling a technically oversold position in the market. The company will introduce a new performance-based dividend policy, committing to distribute at least 40% of earnings per share. This shift follows an 80% cut in dividends for the 2025 financial year, reducing payouts from CHF 0.50 to CHF 0.10 per share. Shareholders will vote on the revised policy at the annual general meeting on April 16, 2026, alongside key board re-elections.
The ex-dividend date is set for April 20, 2026, with payments scheduled for April 22, 2026. Medmix aims to strengthen its financial position through these measures, directing funds toward targeted investments, particularly in healthcare. The half-year financial report, due on July 23, 2026, will provide further insight into the company's performance. While no specific data on Medmix's long-term stock trends is available, broader market pressures—such as restructuring costs and losses seen in other industrial firms—may be influencing investor sentiment. The company's focus remains on stabilising finances and supporting growth initiatives.
The dividend reduction and policy change reflect Medmix's strategy to prioritise financial stability and future investments. Shareholders will review these plans at the upcoming general meeting, with dividend payments set for late April 2026. The company's next financial update in July will offer a clearer picture of its progress.
